中华全科医师杂志XXXX年XX月第XX卷第XX期ChinJGenPract,XXXXXX,Vol.XX,No.XX·1·中国药物性肝损伤基层诊疗与管理指南(2024年)中华医学会中华医学会杂志社中华医学会肝病分会药物性肝病学组中华医学会全科医学分会中华医学会《中华全科医师杂志》编辑委员会中国医药生物技术协会药物性肝损伤防治技术专业委员会中国初级卫生保健基金会药物肝脏安全性专业委员会中国药物性肝损伤基层诊疗与管理指南制定专家组通信作者:茅益民,上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所上海市脂肪性肝病诊治研究中心,上海200001,Email:maoym11968@163.com【关键词】药物性肝损伤;诊断;治疗;疾病管理;指南;基层基金项目:国家重点研发计划(2022YFC35022101);国家科技部“十三五”科技重大专项(2017ZX09304016);国家自然科学基金(81970513,82270619)Chineseguidelinefordiagnosisandmanagementofdrug‑inducedliverinjuryinprimarycare(2024)ChineseMedicalAssociation,ChineseMedicalAssociationPublishingHouse,StudyGroupofDrug‑InducedLiverDisease,ChineseSocietyofHepatology,ChineseSocietyofGeneralPractice,EditorialBoardofChineseJournalofGeneralPractitionersofChineseMedicalAssociation,CommitteeonPreventionandManagementofDrug‑InducedLiverInjury,ChineseMedicalBiotechnologyAssociation,CommitteeonDrugSafetyofLiver,ChinaPrimaryHealthCareFoundation,ExpertGroupofChineseGuidelineforDiagnosisandManagementofDrug‑InducedLiverInjuryinPrimaryCareCorrespondingauthor:MaoYimin,DepartmentofGastroenterology,RenjiHospital,SchoolofMedicine,ShanghaiJiaoTongUniversity,ShanghaiInstituteofDigestiveDisease,ShanghaiResearchCenterofFattyLiverDisease,Shanghai200001,China,Email:maoym11968@163.comFundprogram:NationalKeyR&DProgramofChina(2022YFC3502101);MinistryofScienceandTechnologyMajorProjectofNationalThirteenthFive‑YearPlan(2017ZX09304016);NaturalScienceFoundationofChina(81970513,82270619)药物性肝损伤(drug‑inducedliverinjury,DILI)是指由化学药品、生物制品、中成药等药品,以及中药材、天然药物、保健品、膳食补充剂等产品,或其代谢产物乃至其辅料、污染物、杂质等所导致的肝损伤。基层医疗机构所管理的患者中,普遍存在老年患者较多、多种疾病并存、多药...